HK StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Post-Pandemic Stocks

878.196

-22.449-2.49%

Number of Gainers:3

Number of Losers:11

Number of Flat:4

PE:- -

High:898.976

Open:898.976

Low:863.575

Close:900.645

Loading ...

CSPC Pharmaceutical Group's (HKG:1093) Shareholders Will Receive A Smaller Dividend Than Last Year

Simply Wall St.

Sino Biopharmaceutical's Anti-Tumor Drug Gets Implied Approval from China

MT Newswires Live

Sihuan Pharmaceutical Unit Gets China Nod for Facial Filler

MT Newswires Live

BRIEF-Sihuan Pharma Obtains Approval For Injectable Polycaprolactone Microsphere Facial Filler

Sihuan Pharma - Injectable Polycaprolactone Microsphere Facial Filler Obtained Registration Approval From Nmpa

THOMSON REUTERS

Tong Ren Tang's 2024 Profit Declines 12%

MT Newswires Live

Sihuan Pharmaceutical Increases Investment in Medical Aesthetics Unit; Shares Rise 5%

MT Newswires Live

Ascletis Pharma Reports Positive Interim Results for Obesity Treatment; Shares Up 6%

MT Newswires Live

BRIEF-Sihuan Pharma Says Meiyan Space, Others To Increase Registered Capital Of Meifu Co

Shanghai Fosun Pharmaceutical Raises Stake in United Health Insurance; Shares Rise

MT Newswires Live

Sihuan Pharma - Meiyan Space, Hainan Temmei, and Meifu Co to Increase Registered Capital of Meifu Co From RMB1 Mln to RMB50 Mln

THOMSON REUTERS

BRIEF-Ascletis Announces Positive Interim Results from Its U.S. Phase Ib Trial with ASC30, a Potentially First-in-Class Subcutaneous Injection Small Molecule GLP-1R Agonist

Ascletis Announces Positive Interim Results From Its U.S. Phase Ib Trial With Asc30, a Potentially First-in-Class Subcutaneous Injection Small Molecule Glp-1R Agonist

THOMSON REUTERS

Ascletis Pharma Inc - Asc30 Sq Injection Shows 36-Day Half-Life in Obesity Patients

THOMSON REUTERS

Ascletis Pharma: Announces Positive Interim Results From Its U.S. Phase Ib Trial With Asc30

THOMSON REUTERS

Press Release: Junshi Biosciences Announces 2024 Full Year Financial Results and Provides Corporate Updates

YiChang HEC ChangJiang Pharmaceutical FY Net Income RMB 482.71 Million

THOMSON REUTERS

Tong Ren Tang Technologies Co Ltd - FY Revenue RMB7.26 Bln

THOMSON REUTERS

Tong Ren Tang Technologies FY EPS RMB 0.41

THOMSON REUTERS

Shanghai Junshi Biosciences 2024 Loss Shrinks 44%

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK1515/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1515","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1515\",,,,,undefined,":{"symbol":"BK1515","market":"HK","secType":"PLATE","nameCN":"Post-Pandemic Stocks","latestPrice":878.19635,"timestamp":1743667695040,"preClose":900.64496,"halted":0,"volume":577083918,"delay":0,"changeRate":-0.024925,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":-22.448608,"latestTime":"04-03 16:00:00","open":898.97595,"high":898.97595,"low":863.5754,"amount":4654032983,"amplitude":0.039306,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1743989400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1743643800000,1743652800000],[1743656400000,1743667200000]],"pbRate":1.599835,"peRate":21.344094,"turnoverRate":0.007646,"increases":5,"decrements":12,"flats":1,"marketCap":613578307648,"floatMarketCap":498290330048},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1515\",,,,,undefined,":{"symbol":"BK1515","high":898.97595,"amplitude":0.039306,"preClose":900.64496,"low":863.5754,"pbRate":"1.599835","latestPrice":878.19635,"volume":577083918,"delay":0,"open":898.97595,"prevYearClose":787.97723,"prevWeekClose":881.168,"prevMonthClose":870.015,"prevQuarterClose":870.015,"fiveDayClose":882.434,"twentyDayClose":976.811,"sixtyDayClose":764.008,"secType":"PLATE","market":"HK","turnoverRate":0.007646,"peRate":21.344094,"marketCap":613578307648,"floatMarketCap":498290330048,"timestamp":1743667695040,"nameCN":"Post-Pandemic Stocks"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1515\",,,,undefined,":{"bkCode":"BK1515","up":3,"down":11,"flat":4},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1515\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2525515127","title":"CSPC Pharmaceutical Group's (HKG:1093) Shareholders Will Receive A Smaller Dividend Than Last Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2525515127","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525515127?lang=en_us&edition=fundamental","pubTime":"2025-04-05 06:05","pubTimestamp":1743804339,"startTime":"0","endTime":"0","summary":"CSPC Pharmaceutical Group Limited ( HKG:1093 ) is reducing its dividend from last year's comparable payment to CN¥0.10...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1093/cspc-pharmaceutical-group-shares/news/cspc-pharmaceutical-groups-hkg1093-shareholders-will-receive-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4159","LU1152091168.USD","BK1191","LU0067412154.USD","SG9999004220.SGD","LU0501845795.SGD","LU1008478684.HKD","LU0880133367.SGD","IE0008369823.USD","LU1226287792.SGD","LU1226287529.USD","LU1993786604.SGD","IE00B5MMRT66.SGD","01093","LU1960683339.HKD","IE00B543WZ88.USD","CAGR","IE00B031HY20.USD","BK1521","IE0008368742.USD","IE00BZ08YT58.USD","BK1515","LU0140636845.USD","LU1152091754.HKD","LU1951186391.HKD","IE00BZ08YS42.EUR","LU1807302812.USD","LU0326950275.SGD","LU1226287875.USD","LU1226288253.USD","LU0072913022.USD","IE00BZ08YR35.GBP","LU1226288170.HKD"],"gpt_icon":0},{"id":"2524273305","title":"Sino Biopharmaceutical's Anti-Tumor Drug Gets Implied Approval from China","url":"https://stock-news.laohu8.com/highlight/detail?id=2524273305","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524273305?lang=en_us&edition=fundamental","pubTime":"2025-04-04 15:09","pubTimestamp":1743750574,"startTime":"0","endTime":"0","summary":"Sino Biopharmaceutical's  TQB2101 anti-tumor obtained Chinese implied approval for clinical trials, according to a Thursday filing with the Hong Kong bourse.The drug showed anti-tumor activity in receptor tyrosine kinase-like orphan receptor-1-positive tumor models during preclinical studies, the filing said.ROR-1 is seen in lung, pancreatic, breast, colorectal, and ovarian cancers, the filing said.Separately, China's medical products administrator accepted Sino Biopharm's clinical trial application for its TQB6411 anti-lung cancer drugs.The drug targets the epidermal growth factor receptor and cell mesenchymal epithelial transition present as lung cancer driver genes, according to a separate Thursday filing.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1521","01177","BK1515","BK1589","BK1191"],"gpt_icon":0},{"id":"2524402298","title":"Sihuan Pharmaceutical Unit Gets China Nod for Facial Filler","url":"https://stock-news.laohu8.com/highlight/detail?id=2524402298","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524402298?lang=en_us&edition=fundamental","pubTime":"2025-04-03 14:48","pubTimestamp":1743662933,"startTime":"0","endTime":"0","summary":"China's medical products regulator granted Sihuan Pharmaceutical  subsidiary Meiyan Space Biological Technology  class 3 medical device approval for its injectable polycaprolactone microsphere facial filler.The filler is a regenerative material that helps address facial contour deficiencies and corrects wrinkles in between the nose and lips, according to a Wednesday filing with the Hong Kong bourse.Shares in the aesthetic product company fell 3% during afternoon trading on Thursday.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1191","00460","BK1593","BK1515","BK1600"],"gpt_icon":0},{"id":"2524135418","title":"BRIEF-Sihuan Pharma Obtains Approval For Injectable Polycaprolactone Microsphere Facial Filler","url":"https://stock-news.laohu8.com/highlight/detail?id=2524135418","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524135418?lang=en_us&edition=fundamental","pubTime":"2025-04-02 23:23","pubTimestamp":1743607437,"startTime":"0","endTime":"0","summary":"BRIEF-Sihuan Pharma Obtains Approval For Injectable Polycaprolactone Microsphere Facial Filler April 2  - Sihuan Pharmaceutical Holdings Group Ltd 0460.HK:INJECTABLE POLYCAPROLACTONE MICROSPHERE FACIAL FILLER OBTAINED REGISTRATION APPROVAL FROM NMPAFurther company coverage: 0460.HK ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250402:nFWN3QG0S6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1600","BK1515","BK1191","BK1593","00460"],"gpt_icon":0},{"id":"2524650254","title":"Sihuan Pharma -  Injectable Polycaprolactone Microsphere Facial Filler Obtained Registration Approval From Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2524650254","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524650254?lang=en_us&edition=fundamental","pubTime":"2025-04-02 18:57","pubTimestamp":1743591466,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250402:nFWN3QG0S6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1191","BK1600","00460","BK1593","BK1515"],"gpt_icon":0},{"id":"2524165780","title":"Tong Ren Tang's 2024 Profit Declines 12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2524165780","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524165780?lang=en_us&edition=fundamental","pubTime":"2025-04-01 16:49","pubTimestamp":1743497392,"startTime":"0","endTime":"0","summary":"Tong Ren Tang Technologies'  attributable profit fell 12% to 521.8 million yuan in 2024 from 590.2 million yuan in 2023, according to a Friday filing with the Hong Kong bourse.Earnings per share at the traditional Chinese medicine company decreased to 0.41 yuan from 0.46 yuan in the previous year.Revenue grew 7.2% to 7.26 billion yuan from 6.77 billion yuan a year earlier.The company declared a final dividend of 0.18 yuan per share, similar to last year's dividend. The dividend will be paid on Aug. 11.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["01666","BK1583","BK1515","BK1606","BK1191"],"gpt_icon":0},{"id":"2524157562","title":"Sihuan Pharmaceutical Increases Investment in Medical Aesthetics Unit; Shares Rise 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2524157562","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524157562?lang=en_us&edition=fundamental","pubTime":"2025-04-01 16:03","pubTimestamp":1743494583,"startTime":"0","endTime":"0","summary":"Sihuan Pharmaceutical Holdings Group  made a capital increase in Hainan Meifu Medical Device to increase its presence in the aesthetics market, according to a Tuesday filing with the Hong Kong bourse.Meiyan Space, a non-wholly owned subsidiary of Sihuan, will invest 25.5 million yuan, while Hainan Temmei, a connected party but not a subsidiary of the company, will invest 23.5 million yuan.This move raised Meifu's registered capital to 50 million yuan, with Meiyan holding 51% and Hainan Temmei 49%.The pharmaceutical company's shares were 5% higher in recent trading.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1593","00460","BK1191","BK1600","BK1515"],"gpt_icon":0},{"id":"2524915612","title":"Ascletis Pharma Reports Positive Interim Results for Obesity Treatment; Shares Up 6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2524915612","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524915612?lang=en_us&edition=fundamental","pubTime":"2025-04-01 15:10","pubTimestamp":1743491410,"startTime":"0","endTime":"0","summary":"Ascletis Pharma  posted promising Phase Ib trial results in the U.S. for ASC30, a potential first-in-class GLP-1 receptor agonist for treating obesity, according to a Monday filing with the Hong Kong bourse.A single subcutaneous injection of ASC30 showed a 36-day half-life, supporting once-monthly dosing. The oral tablet form of ASC30 also demonstrated \"6.3% weight loss in patients with obesity after a four-week treatment.\"Ascletis holds global patent protection until 2044 for ASC30.The pharmaceutical shares were up by 5.8%","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","BK1515","BK1574","01672"],"gpt_icon":0},{"id":"2524130214","title":"BRIEF-Sihuan Pharma Says Meiyan Space, Others To Increase Registered Capital Of Meifu Co","url":"https://stock-news.laohu8.com/highlight/detail?id=2524130214","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524130214?lang=en_us&edition=fundamental","pubTime":"2025-04-01 14:04","pubTimestamp":1743487448,"startTime":"0","endTime":"0","summary":"BRIEF-Sihuan Pharma Says Meiyan Space, Others To Increase Registered Capital Of Meifu CoApril 1  - Sihuan Pharmaceutical Holdings Group Ltd 0460.HK:MEIYAN SPACE, HAINAN TEMMEI, AND MEIFU CO TO INCREASE REGISTERED CAPITAL OF MEIFU CO FROM RMB1 MILLION TO RMB50 MILLIONUPON COMPLETION, SHARES OF MEIFU CO WILL BE OWNED AS TO 51% AND 49% BY MEIYAN SPACE AND HAINAN TEMMEIFurther company coverage: 0460.HK ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250401:nFWN3QF003:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1593","BK1515","00460","BK1600","BK1191"],"gpt_icon":0},{"id":"2524137478","title":"Shanghai Fosun Pharmaceutical Raises Stake in United Health Insurance; Shares Rise","url":"https://stock-news.laohu8.com/highlight/detail?id=2524137478","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524137478?lang=en_us&edition=fundamental","pubTime":"2025-04-01 13:46","pubTimestamp":1743486361,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical Raises Stake in United Health Insurance; Shares RiseShanghai Fosun Pharmaceutical   signed a Share Subscription Agreement with IFC and ADB to invest 270 million yuan each in United Health Insurance, according to a Monday filing with the Hong Kong bourse.The deal will increase Fosun Pharma's stake in the insurer from 14.00% to 20.05%. The capital infusion, totaling 810 million yuan, will support the company's expansion. The transaction does not require the approval of independent shareholders.Fosun Pharma views this investment as a strategic move to enhance its presence in China's rapidly growing health insurance sector.The pharmaceuticals shares were up 6% in Hong Kong and 4% in Shanghai in recent trading.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0060","BK1230","BK0175","02196","BK0028","UBCP","BK1191","BK4211","BK0012","00656","BK1515","600196","BK0183","BK1593","BK0096","BK0187","BK0196","BK0239","BK0188"],"gpt_icon":0},{"id":"2524254139","title":"Sihuan Pharma -  Meiyan Space, Hainan Temmei, and Meifu Co to Increase Registered Capital of Meifu Co From RMB1 Mln to RMB50 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2524254139","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524254139?lang=en_us&edition=fundamental","pubTime":"2025-04-01 12:23","pubTimestamp":1743481424,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250401:nFWN3QF003:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1515","BK1600","00460","BK1593","BK1191"],"gpt_icon":0},{"id":"2523491203","title":"BRIEF-Ascletis Announces Positive Interim Results from Its U.S. Phase Ib Trial with ASC30, a Potentially First-in-Class Subcutaneous Injection Small Molecule GLP-1R Agonist","url":"https://stock-news.laohu8.com/highlight/detail?id=2523491203","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523491203?lang=en_us&edition=fundamental","pubTime":"2025-03-31 19:02","pubTimestamp":1743418956,"startTime":"0","endTime":"0","summary":"BRIEF-Ascletis Announces Positive Interim Results from Its U.S. Phase Ib Trial with ASC30, a Potentially First-in-Class Subcutaneous Injection Small Molecule GLP-1R AgonistMarch 31 (Reuters) - Ascleti","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nTUA4T6HRZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1515","01672","BK1574"],"gpt_icon":0},{"id":"2523912791","title":"Ascletis Announces Positive Interim Results From Its U.S. Phase Ib Trial With Asc30, a Potentially First-in-Class Subcutaneous Injection Small Molecule Glp-1R Agonist","url":"https://stock-news.laohu8.com/highlight/detail?id=2523912791","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523912791?lang=en_us&edition=fundamental","pubTime":"2025-03-31 19:00","pubTimestamp":1743418807,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nTUA4T6HRZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1574","BK1515","01672","BK1161"],"gpt_icon":0},{"id":"2523912730","title":"Ascletis Pharma Inc - Asc30 Sq Injection Shows 36-Day Half-Life in Obesity Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2523912730","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523912730?lang=en_us&edition=fundamental","pubTime":"2025-03-31 19:00","pubTimestamp":1743418807,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nTUA4T6HRZ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1574","BK1515","BK1161","01672"],"gpt_icon":0},{"id":"2523912676","title":"Ascletis Pharma:  Announces Positive Interim Results From Its U.S. Phase Ib Trial With Asc30","url":"https://stock-news.laohu8.com/highlight/detail?id=2523912676","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523912676?lang=en_us&edition=fundamental","pubTime":"2025-03-31 18:55","pubTimestamp":1743418510,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nFWN3QE0UL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["01672","BK1515","BK1161","BK1574"],"gpt_icon":0},{"id":"2523465679","title":"Press Release: Junshi Biosciences Announces 2024 Full Year Financial Results and Provides Corporate Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2523465679","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523465679?lang=en_us&edition=fundamental","pubTime":"2025-03-29 09:35","pubTimestamp":1743212100,"startTime":"0","endTime":"0","summary":"SHANGHAI, March 28, 2025  -- Shanghai Junshi Biosciences Co., Ltd , a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial results for the full year of 2024 and provided corporate updates.-- Total revenue of Junshi Biosciences was approximately RMB1,948 million in. 2024, representing an increase of approximately 30% compared to 2023,which was mainly due to the increase in revenue from pharmaceutical. products, in particular: the domestic sales revenue of our core product,toripalimab, was approximately RMB1,501 million, representing an increase. -- Total research and development  expenses of the company were. approximately RMB1,275 million in 2024, representing a decrease of. approximately 34% compared to 2023. The decrease in R&D expenses was. resource allocation and focus on R&D pipelines with greater potential. In. addition, a number of clinical trials of our core product, toripa","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","BK1161","BK1515","R","BK4022","01877","BK1583"],"gpt_icon":0},{"id":"2522509187","title":"YiChang HEC ChangJiang Pharmaceutical FY Net Income RMB 482.71 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2522509187","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522509187?lang=en_us&edition=fundamental","pubTime":"2025-03-28 22:54","pubTimestamp":1743173689,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nPLX1D6617:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["01558","BK1515","BK1191"],"gpt_icon":0},{"id":"2522837574","title":"Tong Ren Tang Technologies Co Ltd - FY Revenue RMB7.26 Bln","url":"https://stock-news.laohu8.com/highlight/detail?id=2522837574","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522837574?lang=en_us&edition=fundamental","pubTime":"2025-03-28 21:02","pubTimestamp":1743166949,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nPLXF7CA22:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1515","BK1583","BK1191","BK1606","01666"],"gpt_icon":0},{"id":"2522571027","title":"Tong Ren Tang Technologies FY EPS RMB 0.41","url":"https://stock-news.laohu8.com/highlight/detail?id=2522571027","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522571027?lang=en_us&edition=fundamental","pubTime":"2025-03-28 21:02","pubTimestamp":1743166949,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nPLXF7CA22:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1515","BK1606","01666","BK1191","BK1583"],"gpt_icon":0},{"id":"2522514022","title":"Shanghai Junshi Biosciences 2024 Loss Shrinks 44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2522514022","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522514022?lang=en_us&edition=fundamental","pubTime":"2025-03-28 15:32","pubTimestamp":1743147130,"startTime":"0","endTime":"0","summary":"Shanghai Junshi Biosciences  reported that loss attributable to owners for 2024 narrowed by 44% to 1.28 billion yuan, from the 2.28 billion yuan loss a year earlier, according to a Thursday filing with the Hong Kong bourse.Loss per share was 1.30 yuan, from 2.32 yuan loss per share a year ago.Revenue rose 30% to 1.95 billion yuan from 1.50 billion yuan the previous year.The company's shares were up 6% at the Hong Kong bourse and 2% at the Shanghai bourse in recent trading.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1515","01877","688180","BK0239","BK1583","BK1161"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":47}]}}